Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Emergent BioSolutions : Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q2 Revenue $397.5M, vs. Street Est of $401.2M

07/29/2021 | 04:09pm EDT


© MT Newswires 2021
All news about EMERGENT BIOSOLUTIONS INC.
09/14Calgary firm advances new trial, manufacturing of mRNA vaccine for COVID-19
AQ
09/14EMERGENT BIOSOLUTIONS : Signs Five-Year, $90 Million Contract With Providence Th..
MT
09/14EMERGENT BIOSOLUTIONS : Secures Multi-Year Development and Manufacturing Agreeme..
AQ
09/14Emergent BioSolutions Inc. Secures Multi-Year Development and Manufacturing A..
CI
09/13EMERGENT BIOSOLUTIONS : FDA - Coronavirus (COVID-19) Update
AQ
09/09EMERGENT BIOSOLUTIONS : Financial Statements and Exhibits (form 8-K/A)
AQ
08/25EMERGENT BIOSOLUTIONS : Launches Late-Stage Trial of Investigational COVID-19 Pl..
MT
08/25Emergent's COVID-19 plasma therapy to be tested in NIH-sponsored study
RE
08/25Emergent's COVID-19 therapy to be tested in NIH-sponsored study
RE
08/25EMERGENT BIOSOLUTIONS : rsquo; COVID-19 Human Immune Globulin Product Candidate ..
AQ
More news
Analyst Recommendations on EMERGENT BIOSOLUTIONS INC.
More recommendations
Financials (USD)
Sales 2021 1 797 M - -
Net income 2021 377 M - -
Net Debt 2021 152 M - -
P/E ratio 2021 8,28x
Yield 2021 -
Capitalization 3 068 M 3 068 M -
EV / Sales 2021 1,79x
EV / Sales 2022 1,77x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 57,14 $
Average target price 83,33 $
Spread / Average Target 45,8%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-36.23%3 068
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604